Bosch lauds new extrusion and calendaring line's API solubility ...
He added that although the main markets for the new line are Europe and the US, manufacturer demand in “ Asia beginning to start up. “. The idea of increasing Asian demand fits with Bosch’s decision to invest €17m ($23m) in a new production... The German firm made the comments after launching a new integrated pharmaceutical melt extrusion and calendaring line that was developed with the pharmaceutical industry’s growing interest in continuous manufacturing in mind. com that: “ Recent conferences as well as research show a strong interest in this [melt] technology due to bad [API] solubility of many new developed APIs. “Furthermore Bosch has invested a lot in integrating field experience – gathered at one of the largest manufacturers of melt extruded products. com at the time Bosch said: “ There are lots of suppliers in the region, and there is a centre for packaging machinery producing companies building up there, so this is a real hot spot for this kind of development. Operator safety was also a consideration during the development of the new system according to Leitze, who added that: “ The complete line is available in containment execution thus suitable for high potent APIs. He explained that the combined line features a ‘brand new’ 40mm screw diameter extruder- the WCF 0040PH - which is capable of producing up to 50kg of drug API per hour.